Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide
in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started
once an optimal dose has been found. The primary endpoint will concern the efficacy of
lenalidomide in patients with CMML according to the WHO diagnostic criteria.